|

JAK1 Inhibitor Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Institute of Hematology & Blood Diseases Hospital, China1

Indications

  • Large Granular Lymphocytic Leukemia1
  • Large Granular Lymphocyte Leukemia1
  • NK-LGL Leukemia1
  • T-LGL Leukemia1
  • Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma1

Other1 trial

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.